scholarly journals Therapeutic Effects of Fibroblast Growth Factor-21 on Diabetic Nephropathy and the Possible Mechanism in Type 1 Diabetes Mellitus Mice

2020 ◽  
Vol 44 (4) ◽  
pp. 566 ◽  
Author(s):  
Wenya Weng ◽  
Tingwen Ge ◽  
Yi Wang ◽  
Lulu He ◽  
Tinghao Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Diabetic Nephropathy ◽  
Growth Factor ◽  
Type 1 Diabetes Mellitus ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Therapeutic Effects ◽  
Fibroblast Growth

scholarly journals Levels of fibroblast growth factor and sulfated glycosoaminoglycans in connective tissue metabolism in patients with mitral valve prolapse and type 1 diabetes mellitus

2021 ◽  
Vol 2021 (1) ◽  
pp. 83-87
Author(s):  
O.Ye. Nikolenko ◽  
◽  
S.B. Pavlov ◽  
O.M. Korzh ◽  
◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Growth Factor ◽  
Mitral Valve ◽  
Type 1 Diabetes Mellitus ◽  
Fibroblast Growth Factor ◽  
Mitral Valve Prolapse ◽  
Control Group ◽  
Fibroblast Growth

In order to study the influence of the main fibroblast growth factor on the indicators of the state of the main substance of the extracellular matrix, a comparative analysis of their levels in the blood serum was carried out in persons with mitral valve prolapse and type 1 diabetes mellitus. The data obtained showed that the highest level of FGF-2 was observed in patients with a combination of MVP and type 1 diabetes mellitus compared with isolated MVP and diabetes, the control group (p <0.01) Level II of the GAG ​​fraction, which is represented in the main substance of the extracellular the matrix of the heart valve apparatus was also the highest in comorbid pathology, significantly differing from the control group (p <0.05). The level of GAG fraction III was higher among diabetic patients, regardless of the presence or absence of MVP, which is associated with the localization of this GAG fraction in the basement membranes of blood vessels and may be one of the elements of the pathogenesis of diabetic angiopathy

scholarly journals The study of fibroblast growth factor-2, sulfated glycosaminoglycans and oxyproline with mitral valve prolapse in combination with type 1 diabetes mellitus

2021 ◽  
pp. 9-15
Author(s):  
Olena Nikolenko ◽  
Oleksiy Korzh
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Growth Factor ◽  
Mitral Valve ◽  
Fibroblast Growth Factor ◽  
Mitral Valve Prolapse ◽  
Fibroblast Growth Factor 2 ◽  
Control Group ◽  
Fibroblast Growth

The aim. The aim of the study was to conduct a comparative analysis of fibroblast growth factor-2, the total content and fractions of sulfated glycosoaminoglycans as well as free and peptide-bounding oxyproline as the markers of connective tissue metabolism in young patients with mitral valve prolapse, type 1 diabetes mellitus and the combination of both indications. Materials and methods. 93 patients between 19 and 33 years old with either mitral valve prolapse, or type 1 diabetes or the combination of both indications were examined. Group 1 was represented by 36 patients with the monomorbid type 1 diabetes mellitus. Group 2 consisted of 33 patients with type 1 diabetes mellitus and mitral valve prolapse. The comparison group included 24 people with diagnosed mitral valve prolapse. The concentration of fibroblast growth factor-2 in blood plasma was determined by the enzyme immunoassay using a Quantikine reagent kit (Human FGF basic Immunoassay), manufactured by R&D Systems, Inc. (USA) and expressed in pg/ml. The total content and fractions of glycosaminoglycans in blood serum were determined by the method of N. G. Stern et al. and expressed in units of optical density. The level of free and peptide-bounding oxyproline in blood serum were determined by the method of P. N. Sharaev and expressed in µmol/L. Results. Fibroblast growth factor-2 was higher in group 2, where it was 23.7±0.25 pg/ml compared to the control group – 14.20±0.22 pg/ml (p <0.01). There was also a significant difference in the levels of fibroblast growth factor-2 between groups 1 where it equaled 15.33±0.24 pg/ml and 2 – 23.71±0.25 pg/ml (p<0.01). The total content of glycosaminoglycans in comparison with the control group, where it was equal to 9.7±0.62 odu, was higher in all groups of patients: in group 1 it was 12.07±1.04 odu, in the comparison group it was 11.75±0.83 odu, in the group with the combined pathology it was 13.32±1.59 odu (p<0.05). The values of glycosaminoglycans II fraction, were higher in group 2 – 4.96±0.59 odu. The level of peptide-bound oxyproline, just as the level of free oxyproline, significantly increased in patients with comorbid pathology in group 2, compared to the control group: 16.06±1.54 µmol/l versus 8.7±0.81 µmol/l (p<0.01) respectively. Conclusions. The values of fibroblast growth factor-2, glycosaminoglycans II fraction, free and peptide-bound oxyproline were significantly higher in patients with diabetes mellitus and mitral valve prolapse in comparison with the control group. Fibroblast growth factor-2 was higher in patients with comorbid pathology compared to the monomorbid diabetes patients.

Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice

2016 ◽  
Vol 130 (8) ◽  
pp. 625-641 ◽  
Author(s):  
Jingjing Zhang ◽  
Yanli Cheng ◽  
Junlian Gu ◽  
Shudong Wang ◽  
Shanshan Zhou ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Cardiac Dysfunction ◽  
Lipid Lowering ◽  
Fibroblast Growth Factor 21 ◽  
Dependent Manner ◽  
Fibroblast Growth ◽  
Diabetic Mice

Fenofibrate (FF) as a commonly-used lipid-lowering medicine in clinics was examined for its potentially repurposing to prevent the cardiac abnormalities in patients with type 1 diabetes. We demonstrated here that fenofibrate significantly prevented diabetes-induced cardiac dysfunction and remodeling in fibroblast growth factor 21 (FGF21)-dependent manner.

Sign in / Sign up

Export Citation Format

Share Document